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Abstract 
Over twelve percent of women aged fifteen to forty-five in America suffer from 
infertility and/or impaired fecundity and over seven million women have used infertility services, 
such as intrauterine insemination and ​in vitro​ fertilization. Some cases of infertility may be due 
to dysfunctional human follicle stimulating hormone (hFSH) signaling. hFSH plays a role in 
spermatogenesis in males, as well as follicle maturation and estrogen production in females. 
Problems with either hFSH or the hFSH receptor (hFSHR) decrease fertility in males and cause 
complete infertility in females. As part of the hypothalamic-pituitary-gonadal axis, hFSH is 
released from the pituitary gland and binds to hFSHR in the ovaries and testes.  
It has been shown that hFSHR interacts with lipid rafts, stiffer regions of the plasma 
membrane with higher sphingolipid and cholesterol concentrations, and with caveolin, a protein 
found in certain lipid rafts. This interaction may occur through a specific sequence of amino 
acids in the 4th transmembrane domain of the hFSHR consistent with a caveolin interaction 
motif (CIM). Previous work from our lab also suggested that hFSHR signaling is regulated 
through residency in lipid rafts, such that hFSHR signaling is inhibited as a result of recruitment 
into lipid rafts.  
The current study investigated the effect of mutations of the CBM and of MBCD 
treatment on hFSHR signaling. It was hypothesized that complex mutation of the CBM would 
cause increased hFSHR signaling by disrupting interactions with caveolin, preventing inhibition 
via residency in lipid rafts. Mutants were created using site-directed mutagenesis and expression 
vectors were transiently transfected into HEK293 cells and hFSHR signaling was qualitatively 
compared between mutants via western blot. Mutation of two sites in the CBM resulted in 
increased basal and induced hFSHR signaling. It was also hypothesized that MBCD treatment 
would lead to increased signaling, but an EPAC-based FRET assay found that cholesterol 
depletion decreased hFSHR signaling to near nothing. Further understanding of hFSHR signaling 




About six percent of married American women aged 15 to 44 suffer from infertility, 
while about 12 percent of all American women in the same age group suffer from impaired 
fecundity (1). Infertility is defined as the inability to conceive after trying for one year or longer, 
while impaired fecundity is defined as difficulty getting and staying pregnant to carry a fetus to 
term (1). Infertility affects men, as well, with the male playing a role in about 35 percent of 
infertile couples’ struggles and being solely responsible for the infertility of about eight percent 
of couples (1). 
 The process of conception 
is complicated, leaving a plethora 
of places where the process can 
halt or occur improperly. For 
example, sperm can be immobile or 
generated with the incorrect 
proteins needed for recognition by 
the egg (1). Both of these problems 
alone can render a couple infertile, 
even if the woman’s reproductive 
system is functioning perfectly. In 
women, follicles can fail to 
correctly mature, the ovaries can fail to release a mature oocyte during ovulation, there can be a 
structural barrier to the travel of the egg and sperm through the fallopian tubes, or the 
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endometrial lining can be poorly made and unsuitable for implantation of an embryo (Figure 1) 
(1). Again, all of these issues can render a woman completely infertile or result in impaired 
fecundity, and this is not an exhaustive list of complications when trying to conceive. 
Infertility treatments include medications, surgery, and artificial reproductive technology 
(ART), or direct manipulation of the egg and/or sperm to achieve conception. Medications for 
infertility typically act to balance out abnormal hormone levels that may be causing infertility. In 
men, these medications normally aim to increase the number and quality of sperm produced, 
while medications for women typically try to regulate or induce ovulation (2). For example, 
medications such as Letrozole, hMG, and Follistim act directly on the ovaries, while Clomid acts 
on the pituitary, all with the same effect of prompting ovulation by correcting issues within the 
female hormone signaling pathways (2). While not as common as medications and ART, some 
women require surgery to remove a uterine septum, endometrial polyps, damaged or malformed 
fallopian tubes, or endometrial tissue that grew abnormally due to endometriosis (2,3).  
Intrauterine insemination (IUI) involves the collection of a sperm sample and the direct 
injection of the sperm into the uterus around the time of ovulation (3). This increases the chances 
of conception because the sperm are directly placed in the uterus and thus have a shorter distance 
to travel, making a more direct pathway to conception than during intercourse. IUI, along with 
hormone treatments, can help a couple conceive in light of low sperm count or low sperm 
motility (3). 
ART represents the most profitable side of the infertility field. ART techniques include 
egg/sperm donation, ​in vitro​ fertilization, the use of a gestational surrogate, and assisted hatching 
(2). ART techniques have the highest success rates, but they are very expensive and are not 
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always covered by insurance plans (3). ​In vitro​ fertilization (IVF) is the most common ART used 
and involves the removal of eggs from the ovaries, fertilization with sperm from the desired 
donor in the laboratory, and subsequent placement of embryos into the uterus for implantation 
(Figure 2) (3). Like 
natural conception, the 
percentage of women 
who are able to 
conceive using IVF 
decreases with age, with 
a national success rate 
of 31% for women 
under age 35 and 3% for 
women over age 44 (1).  
A study from 2010 found that the average annual cost of medication for women 
undergoing infertility treatments was $1,182, while the average total cost for a woman to 
successfully conceive in 18 months or less using IVF was over $61,000 (4). Still, not every 
patient will successfully conceive in 18 months and not every conception via IVF leads to a live 
birth. In addition to the financial burdens that infertility treatments can place on a patient, 
infertility can also cause additional stress and poor mental health. Studies between 1992 and 
2004 found higher prevalence rates of major depression in infertile couples as compared to their 
fertile counterparts, with at least one member of 15-54% of infertile couples reporting symptoms 
of major depression (5). Studies between 2000 and 2004 found similar results for symptoms of 
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clinical anxiety, with 8-28% of infertile couples reporting that at least one member of the couple 
was experiencing anxiety (5). Together, these results suggest that infertility puts couples at 
higher risk of mental health problems on top of the financial burdens that can result from 
infertility. 
Between one and two percent of American women undergo IVF treatment annually, 
suggesting that the field of infertility is both incredibly profitable and relevant to the American 
population, justifying further study of human reproduction (4). Moving forward, research 
regarding human reproduction should aim to increase the percent of patients who successfully 
conceive while lowering the costs of these treatments. 
All infertility treatments are based on the normal functions of the human reproductive 
system, attempting to emulate those normal functions in patients where the reproductive system 
does not work correctly on its own. The human reproductive system is regulated by hormones- 
chemical messengers created in one cell to act on another cell. Most hormones involved in 
reproduction are endocrine hormones, which are made in one organ, introduced into the 
bloodstream, and act on target tissues around the body. Endocrine hormones are used to regulate 
many systems in the body in large axes that include multiple organs and levels of control to 
allow for the up- and down-regulation of certain organ functions to maintain homeostasis. Such 
axes include the hypothalamic-pituitary-adrenal axis, or the HPA axis, and the 
hypothalamic-pituitary-thyroid axis, or the HPT axis (6). 
The hypothalamic-pituitary-gonadal, or HPG, axis represents the hormonal pathway that 
regulates the reproductive system in both males and females. The hypothalamus is a type of 
neural control center in the forebrain that helps regulate many aspects of homeostasis within the 
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body, such as temperature control, hunger, thirst, and circadian rhythms. Hanging directly below 
the hypothalamus in the midbrain is the pituitary gland, which is composed of many different 
cell types. When stimulated by hypothalamic hormones, these cells secrete various hormones 
that are named in correlation with the cell types that produce them. In the HPG axis, the 
hypothalamus releases gonadotropin-releasing hormone, GnRH, in waves. GnRH targets the 
gonadotrophs in the anterior pituitary, which release gonadotropin hormones, including human 
luteinizing hormone, hLH, and human follicle stimulating hormone, hFSH. These hormones bind 
to G protein-coupled receptors on gonadal cells, activating signaling pathways that lead to 
correct reproductive function (6).  
In males, hLH targets the Leydig cells in the testes to stimulate testosterone production. 
hFSH and testosterone together 
target the Sertoli cells of the 
testes to stimulate 
spermatogenesis, or the formation 
of sperm cells. Spermatogenesis 
prompts the Sertoli cells to begin 
producing inhibin, and inhibin 
and testosterone act together on 
the pituitary gland to inhibit the 
production of more hFSH, 
finishing the feedback loop that 
governs male reproduction. 
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Testosterone also inhibits GnRH production from the hypothalamus to shut down the signaling 
pathway earlier and stimulates the development and maintenance of male secondary sex 
characteristics (Figure 3) (7).  
In women, hFSH and hLH both act on the follicular cells of the ovaries, leading to 
estradiol and progesterone production, as well as follicle maturation. Follicles are small sacs 
within the ovaries that nurture the developing egg cells. Progesterone signals for growth of the 
endometrium to prepare for pregnancy, and estradiols support development and maintenance of 
female secondary sex characteristics. As the follicles mature, they produce inhibin, similar to the 
Sertoli cells of the testes in men, which 
acts on the pituitary to decrease hFSH 
production. A surge of hLH from the 
pituitary in the middle of the menstrual 
cycle causes the follicle to burst, releasing 
the egg in an ovulation event. After 
ovulation, the ruptured follicle cell is 
called a corpus luteum and produces 
progesterone that inhibits hFSH and hLH 
production from the gonadotrophs of the 
anterior pituitary and GnRH production 
from the hypothalamus, shutting down 
hFSH production (Figure 4). The 
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endometrial lining will either be shed and re-formed or maintained to support a pregnancy, 
depending on whether or not the ovulated egg becomes fertilized and successfully implants (7). 
Yet, hormones are only as useful as their receptors, so a functioning reproductive system 
relies heavily on working receptors for hFSH and hLH in the gonads. The hFSH receptor, 
hFSHR, is a G protein-coupled receptor. G protein-coupled receptors are membrane proteins 
with 7-transmembrane domains, an extracellular domain that receives signals from the cell’s 
environment, and an intracellular domain that allows for the propagation of the extracellular 
signal through to the interior of the cell (Figure 5). In typical G protein-coupled receptors, the 
intracellular domain interacts with a heterotrimeric G protein. These G proteins consist of alpha, 
beta, and gamma subunits. When the extracellular domain of a G protein coupled receptor binds 
a hormone from the cell’s environment, the intracellular domain catalyzes the exchange of a 
guanosine diphosphate 
(GDP) molecule for a 
guanosine triphosphate 
(GTP) molecule bound to 
the alpha subunit of the 
heterotrimeric G protein. 
This causes the alpha 
subunit of the G protein to 
separate from the 
beta/gamma joint-subunit. 
Both the alpha subunit and the beta/gamma subunit can signal inside the cell by activating 
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secondary signaling molecules, allowing for complex intracellular responses to one extracellular 
signal. This signaling will continue until the alpha subunit of the G protein catalyzes the 
hydrolysis of GTP to GDP and Pi, when the beta/gamma subunit re-joins the alpha subunit. The 
G protein remains in its heterotrimeric state, bound to GDP, until the G protein-coupled receptor 
is activated again to catalyze the exchange of GDP for GTP once again (9).  
The intracellular signaling pathways activated by hFSHR are complex and not 
completely understood, but there are three secondary signaling molecules that are of importance 
in both the ovaries and the testes for research purposes. Through activation of adenylyl cyclase, 
adenosine triphosphate (ATP) is converted to cyclic adenosine monophosphate (cAMP) which 
then allows for the phosphorylation of cAMP response element binding protein (CREB) to 
phospho-CREB by protein kinase A (8). hFSHR signaling also yields the activation of 
beta-arrestin, allowing for activation of the MAPK pathway, resulting in the phosphorylation of 
p44 to phospho-p44 (8). cAMP, phospho-CREB, and phospho-p44 can be detected in 
biochemical assays and, therefore, used to identify hFSHR signaling based on the activation of 
these intracellular pathways.  
Since human reproduction is a complex process, and hFSH, along with other hormones, 
has multiple roles in the process, there must be a way to regulate hFSH signaling within the cells 
to allow for complex regulation of downstream effects. The signals need to be timed correctly so 
that hFSHR signaling is only active when necessary, implying that a regulation mechanism exists 
to halt hFSHR signaling when the downstream effects are no longer needed. Previous studies in 
our lab have shown that hFSHR is present in  lipid rafts fractions of a discontinuous sucrose 
gradient, suggesting an interaction between the two (9). This interaction may provide a 
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mechanism for signaling regulation, given that lipid rafts have been found to play a role in 
signaling (10). Lipid rafts are areas within the plasma membrane that have higher cholesterol and 
sphingolipid concentrations than the rest of the membrane, making them stiffer than the 
membrane around them (9). The difference in membrane composition between lipid rafts and the 
other regions of the membrane is thought to allow for colocalization or de-localization of 
signaling components, allowing for increased or decreased signaling capabilities, respectively 
(10). It has also been found that lipid rafts recruit signaling molecules into them, further 
suggesting that they allow for spatially-coordinated approaches to signaling, bringing together 
molecules that, until now, were thought to float freely through the plasma membrane (11). For 
example, IgE signaling in basophil cells seems to occur more efficiently when coordinated via 
lipid rafts (10).  
Caveolae are a 
specific type of lipid raft 
that contain at least one of 
the caveolin proteins, a 
type of scaffolding 
protein, and take on a 
cone-like shape within the 
membrane, which is 
structured mostly from 
caveolin-1 and caveolin-3 
(Figure 6) (12). Like other 
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types of lipid rafts, caveolae are known to have high concentrations of signaling molecules, 
making them interesting in hormone signaling regulation (12). Interactions between caveolin and 
G protein-coupled receptors have been investigated broadly with results suggesting that caveolin 
plays a role in inhibiting G protein-coupled receptor signaling pathways by trafficking proteins 
into lipid rafts (13). A study of caveolin knockout mice further supports the idea that caveolin 
plays a role in regulating signal transduction. Knockout mice lines were generated for 
caveolin-1, -2, and -3, and demonstrated pathologies related to signaling molecules and ion 
channels in the cardiovascular, pulmonary, urogenital, skeletal, neural, and endocrine systems, as 
well as increased susceptibility to cancer (14). 
Scientists have identified a specific sequence of ten amino acids that is found in many 
proteins that interact with caveolin, also called the caveolin binding motif or caveolin interaction 
motif (15). This sequence of ten amino acids follows a φXφXXXXφXXφ pattern, where φ 
represents an aromatic amino acid residue, which are considered to be the functional units of this 
motif, and X represents any other amino acid residue (15). This motif is found in the hFHSR 
protein sequence, specifically in the fourth transmembrane domain. In order, the aromatic 
residues in this motif when found in the hFSHR sequence are colloquially referred to as the A, B, 
C, and D sites, which lie at residue positions 479, 481, 486, and 489, respectively. When viewed 
in a three-dimensional model, the B site is oriented opposite from the A, C, and D sites, 
suggesting that the B site may play a smaller role in the function of this motif because it is 
separated from the other functional units of the binding motif (Figure 7). Sequences of this 
pattern have been found in up to thirty percent of human proteins with known sequences, but not 
all of them appear to interact with caveolin (15). However, previous evidence from our lab also 
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suggests that hFSHR co-immunoprecipitates with caveolin-1 (9). Since lipid rafts are thought to 
play a role in signaling regulation, caveolin has been found to move proteins into lipid rafts, the 
hFSHR sequence includes a caveolin 
binding motif, and hFSHR has been 
found to co-immunoprecipitate with 
both lipid rafts and caveolin-1, this 
motif is of interest in further 
understanding hFSHR signaling 
regulation. 
Additionally, the role of lipid 
rafts should be investigated 
independently of caveolin, as the 
lipid rafts may play a role in 
signaling regulation separate from that of caveolin. One way to investigate lipid rafts directly is 
to disrupt their structure by removing the cholesterol from them. Methyl-beta-cyclodextrin, 
MBCD, has been shown to successfully lower cholesterol levels in cells, and established 
protocols have been suggested on how to do this without killing the cells (16). MBCD and other 
cyclodextrins have a large hydrophobic cavity which causes cholesterol to leave the cell 
membrane and enter the cavity, thus lowering the effective cholesterol concentration of the cell 
(15). Given the higher concentration of cholesterol in lipid rafts versus the rest of the plasma 
membrane, the lipid rafts would be affected more severely by MBCD treatment, causing them to 
lose their unique composition and become more like the rest of the plasma membrane.  
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Human thyroid stimulating hormone, hTSH, is an endocrine hormone in the 
hypothalamic-pituitary-thyroid axis with a structure very similar to that of hFSH (6). The hTSH 
receptor (hTSHR) has been found to interact with caveolin during signaling regulation (17). 
Lipid raft depletion using MBCD and caveolin knockdown both resulted in increased hTSH 
signaling, identified by looking for increasing cAMP concentrations, as cAMP is also produced 
in the intracellular pathways controlled by hTSHR activation (17). After MBCD treatment, 
hTSH signaling could not be regulated by lipid rafts because there were no lipid rafts present. 
Similarly, caveolin knockdown depleted the number of caveolae the cell could produce, making 
it unlikely that hTSH signaling could be regulated by caveolae, specifically. The increased hTSH 
signaling identified here after MBCD treatment and after caveolin knockdown suggests that 
interactions with lipid rafts in general and/or caveolae, specifically, are regulating hTSH 
signaling pathways in the cells (17). 
A similar study to that performed with hTSH and hTSHR was performed in our lab using 
hFSH and hFSHR, 
which showed that 
depletion of the 
cholesterol content 
of a cell using 
MBCD is correlated 
with an increase in 
hFSH signaling as 
identified via 
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western blot probing for phospho-CREB and phospho-p44. This suggests that hFSH signaling is 
regulated via residency in lipid rafts. These results further support the aforementioned studies 
linking receptor-lipid raft interactions to signaling regulation. The author of this study concluded 
that hFSR binding to hFSHR caused internal signaling from hFSHR, along with relocation of 
hFSHR to lipid rafts, and that this relocation signaled for internalization of the receptor (Figure 
8). Internalization of a receptor halts its signaling, so it was concluded here that residency in lipid 
rafts causes a net decrease in hFSHR signaling. Thus, when the lipid rafts were eliminated by 
MBCD treatment, there was no regulation mechanism in place to stop the receptor from 
signaling continuously (18).  
To evaluate the role of caveolin in this regulation mechanism, some hFSHR mutants were 
created using site-directed mutagenesis of the aromatic residues in the caveolin binding motif. 
Preliminary testing of these mutants via western blotting probing for phospho-CREB found 
possibly increased signaling in the mutants as compared to the wild type receptor (18). 
Based on the data suggesting hFSHR signaling is regulated by lipid raft residency and the 
preliminary results suggesting a possible role of caveolin in the regulation, the current study 
sought to further investigate the role of lipid rafts and caveolin in hFSHR signaling regulation. 
More complex hFSHR caveolin interaction motif mutants were created with various 
combinations of changes at the A, B, C, and D sites and the signaling from these mutants was 
analyzed using western blotting and an EPAC-based FRET assay to investigate the role of the 
interaction between caveolin and the receptor in signaling. Based on the hypothesis generated by 
Wells and Cohen (2017), it was hypothesized that this study would find increased signaling from 
the hFSHR mutants due to the lack of hFSHR-caveolin interactions to allow for signaling 
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regulation. Further, due to the spatially isolated nature of the B site in the caveolin binding motif, 
it was hypothesized that mutation of the B site would yield a smaller change in signaling than 
mutations of the A, C, and D sites due to its orientation away from the other aromatic 
residues.The EPAC-based FRET assay was also used to analyze hFSHR signaling after MBCD 
treatment to investigate the role of lipid rafts more generally on signaling. Similar to our other 
hypotheses, we hypothesized that MBCD treatment would cause increased signaling because 
there would be no lipid rafts for the receptor to reside in, meaning there could be no signaling 




The human embryonic kidney 293, or HEK293, cell line was used in all experiments 
because it is easily transfected (19). The HEK293 line was transiently transfected to express 
mutant hFSHR sequences, as described below, and two lines of HEK293 cells were maintained 
for the CANDLES assay, one stably transfected with a genetically modified version of the 
exchange factor directly activated by cAMP (EPAC) protein and one with the wild type hFSHR 
sequence. Lines were maintained using standard eukaryotic culture methods and antibiotic 
selection to maintain transfection status.  
 
Mutagenesis: 
The New England Biolabs Q5 Site-Directed Mutagenesis Kit and protocol was used to 
mutate the caveolin interaction motif within the hFSHR gene on a pIRESneo plasmid template 
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(20). Primers were developed using the NEBaseChanger online primer design tool from New 
England Biolabs and ordered to introduce the desired mutations (phenylalanine to leucine) in the 
motif at the A, B, C, and D sites. Mutagenesis was completed per the Kit protocol, consisting of 
PCR with the mutant-inducing primers, a KLD reaction to form plasmids from the PCR product, 
and heat shock to transform the plasmids into the New England Biolabs 5-alpha Competent ​E. 
coli​ (High Efficiency) (#C2987) chemically competent cells provided with the Kit (20). This 
site-directed method allowed for complex mutations to be made on the same plasmid by carrying 
out the mutagenesis protocol on an already-mutated plasmid. For example, an AB mutant could 
be made by using mutation-inducing primers specific to the B site on a plasmid already mutated 
at the A site.  
The plasmid preparations with mutant hFSHR sequences were stored in a zero degree 
Celsius freezer until transfected into cells. Mutations were designed specifically to put a new 
restriction enzyme site at each mutation site, allowing for detection of successful mutagenesis by 
restriction enzyme digest. Successful mutation of the A site added a BamHI digestion site, while 
mutation of the B site resulted in a NheI digestion site, of the C site resulted in an EarI digestion 
site, and of the D site resulted in an AvrII digestion site. Restriction digests with all enzymes 
were performed, and the products run through a 2% agarose gel electrophoresis, to ensure 
successful mutation of all desired sites. 
 
Transfections: 
HEK293 cells were split lightly into 6-well tissue culture plates and left to grow for about 
72 hours. The plasmid preparations were thawed to room temperature prior to transfection. The 
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Mirus TransIt-293 transfection reagent was used according to its published protocol to encourage 
uptake of the hFSHR mutant plasmid DNA by the HEK293 cells (21). After treatment with the 
transfection solution described in the protocol, cells were left to incubate for 24-72 hours before 
proceeding with isolation of protein for western blot analysis or replating of the cells for a 
CANDLES assay. 
 
Isolation of protein from transfected cells: 
Cells were incubated at 37 degrees Celsius in serum-free media for one hour to induce a 
state of starvation and eliminate all non-essential metabolic reactions and signaling activation 
prior to protein isolation. Cells were then treated with hFSH for varied amounts of time. Urinary 
hFSH was added at a four micromolar concentration, and pituitary hFSH at a two micromolar 
concentration. Protein samples were obtained from the transiently transfected cells using lysis 
buffer and douncing to break open the cells, followed by centrifugation to separate all cell debris 
from the protein fraction. The protein fractions were stabilized with a sample dye containing 
EDTA and stored in a zero degrees Celsius freezer until run in a SDS-PAGE/western blotting 
protocol. 
 
Signaling analysis using western blotting: 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate the proteins samples isolated from each cell type by size. The gels were made using a 
stacking gel and running gel to help ensure even run times for each protein within a lane. 
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After SDS-PAGE, the protein samples were transferred to a Immobilon-P transfer 
membrane using a semi-dry transfer method and a BioRad Trans-Blot SD Semi-Dry Transfer 
cell. All membranes were probed first for phospho-p44 using a goat/anti-rabbit secondary 
antibody to evaluate for activation of hFSHR signaling in the cells, followed by probing for 
follitropin receptor with mAB 106.105, an hFSHR specific monoclonal antibody and a 
goat/anti-mouse secondary antibody to evaluate for hFSHR presence. Together, both probing 
results allowed for a relative comparison of signaling between mutants, with second probing 
images providing context for the efficiency of each transfection reaction. 
 
Signaling analysis using CANDLES assay: 
The cyclic-AMP indirect detection by light emission from sensor cells, CANDLES, assay 
is an EPAC-based FRET assay originally described in a 2014 paper out of Finland (22). HEK293 
cells stably transfected with a gene coding for a genetically-engineered version of the EPAC 
protein were sent to us from the authors of the paper for use here. These EPAC cells serve as the 
sensor cells for this assay. The EPAC protein expressed in these cells has a FRET donor and 
acceptor added on either end of the protein sequence. When EPAC is not bound to cAMP, the 
FRET donor and acceptor are physically close to each other and FRET occurs, causing the 
release of 530 nanometer light when the molecule is excited by 430 nanometer light. When 
EPAC binds cAMP, it undergoes a conformational change that moves the FRET acceptor away 
from the donor so that FRET no longer occurs. The protein then emits 475 nanometer light, 
instead (22).  
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When these EPAC sensor cells are co-cultured with donor cells, the HEK293 cells 
transfected with the wild type hFSHR gene, the cells form gap-junctions with each other, 
allowing for transfer of cAMP from the donor cells to the sensor cells. Since cAMP is produced 
as a result of hFSHR activation, and the ratio of non-FRET to FRET light emission represents 
the amount of cAMP present, this creates a relationship between the hFSHR signaling in the 
donor cells and changes in the non-FRET to FRET ratio detected from the sensor cells. Thus, an 
increase in this ratio correlates to an increase in cAMP levels, which indicates an increase in 
hFSHR signaling (22). 
The EPAC cells are also activated by forskolin in a way that leads to cAMP production, 
allowing EPAC cells to serve as a positive control by being plated by themselves and treated 
with forskolin. HEK293-hFSHR cells 
plated without EPAC cells serve as a 
negative control, given that these cells 
should not be florescing at all. 
The donor and sensor cells are 
plated into a 96-well 
fluorescence-compatible 
tissue-culture-treated plate and left to 
incubate for 48 hours. The ratio of 
HEK293-EPAC cells to 
HEK293-hFSHR cells was manipulated 
to find the ideal ratio to be 1:1. The cells 
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are first put in serum-free media and incubated at 37 degrees Celsius for one hour to induce a 
state of starvation and eliminate all non-essential metabolic reactions and signaling activation 
prior to the assay. If applicable, MBCD  treatment was also given during this one hour 
incubation period by adding MBCD to the serum-free medium at a five micromolar 
concentration. A “blank” read is taken on a fluorescence spectrophotometer to obtain the level of 
fluorescence emitted with initial levels of cAMP in the EPAC cells. Cells are then treated with 
urinary hFSH added at a four micromolar concentration or pituitary hFSH at a two micromolar 
concentration. Immediately after spiking with hFSH, a kinetic read is taken on the 
spectrophotometer, tracking changes in the non-FRET/FRET ratio over time while the cAMP 




Most of the 
complex mutations of 






technique, except the 
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AC, AD, BD, and ABD mutants. All mutants were verified via restriction digest and agarose gel 
electrophoresis, indicating successful mutagenesis (Figure 9). Four attempts at making the ABD 
mutant failed. 
 
Signaling from hFSHR caveolin interaction motif mutants: 
Western blots of hFSHR mutants probed for phospho-p44 and the follitropin receptor 
showed increased basal and induced activation from double mutants, or receptors mutated at two 
of the four aromatic sites in the caveolin interaction motif, but gave mixed results for the triple 
mutants (Figures 10 and 11). Compared to the wild type receptor, the phospho-p44 bands on the 
blots for the double mutants were more intense for both basal and induced signaling when 









from the BCD 
triple mutant, 
as shown in 
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Figure 10, while others showed increased induced activation from the ABC triple mutant and 
increased basal activation from the ACD triple mutant, as shown in Figure 11. Bands for the 
quadruple mutant for both phospho-p44 and the follitropin receptor showed lane streaking and 
were too thick to interpret (Figure 11). 
A CANDLES assay was run using the ABC, ACD, BCD, and ABCD mutants, as well. 
The results of this assay were inconclusive; the positive controls did not respond as expected, so 
no conclusions were drawn. 
 
Signaling after MBCD treatment: 
Control cells showed near linear increases in non-FRET/FRET ratio with increasing 
hFSH concentration, as expected (Figure 12). Cells treated with MBCD showed almost no 
changes in 
non-FRET/FRET ratio 
at all doses of hFSH as 
compared to control 
cells (Figure 12). The 
differences in the net 
change in FRET ratio 
between the control and 
MBCD treated cells 
were statistically 
significant at the 0.2, 
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1.0, and 2.0 nanogram per milliliter concentrations of hFSH, with a statistical significance level 
of p < 0.05 (Figure 12).  
 
Discussion 
Site-directed mutagenesis was mostly successful to make the mutant hFSHR plasmids, 
but failed when attempting to insert a mutation at the D site. It is possible that the mutant primers 
for the D site did not bind to the template DNA strongly enough to allow for successful 
amplification during the polymerase chain reaction. Since the C and D sites are so close to each 
other in the sequence, the mutation of the D site after the C site may be more difficult because 
the mutant primers for the D site are not designed to bind to the mutated C site. Future research 
should consider using a splicing by overlap extension method to mutate the D site, which may 
help get around this issue without buying all the possible combinations of primers in an attempt 
make the polymerase chain reaction more successful.  
The increased basal and induced receptor activation seen from the mutant receptors in the 
western blots supports the hypothesis that mutating the caveolin interaction motif would lead to 
increased signaling, presumably due to interruption of interactions between hFSHR and caveolin 
(Figure 10). Based on the data from last year’s theses, it would seem that this is occurring 
because caveolin helps traffic the receptor into lipid rafts, where their signaling is shut off. 
However, we have no conclusive results regarding the triple mutants or the quadruple mutant 
(Figures 10 and 11). The mixed results from the triple mutants cannot be reliably interpreted, and 
the bands representing both the phospho-p44 and follitropin receptor isolated from the quadruple 
mutant are too concentrated to interpret. The streaking in the lanes for the quadruple mutant, 
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along with the thicker, blurrier nature of the bands, suggests that the lanes were overrun with 
protein during the SDS-PAGE protocol and possibly indicate an error during the BCA assay. 
Due to the inconclusive results for the triple and quadruple mutants, no conclusions can be made 
about the relative role of the B site versus that of the A, C, and D sites in the caveolin interaction 
motif.  
The CANDLES data regarding MBCD treatment does not support our hypothesis, 
indicating that decreased cholesterol content in the cell, and presumably decreased lipid raft 
prevalence in the plasma membrane, actually leads to a drop hFSHR signaling, even with 
increased hFSH concentration (Figure 12). If cholesterol was playing a role in signaling through 
lipid rafts, as previously thought, the signaling should have increased because lipid raft residency 
would have been prevented and the receptor would never have been internalized. The difference 
in signaling between the control and MBCD treated cells here suggests that cholesterol is integral 
for hFSHR signaling, just not through lipid rafts. 
This data matches some older data from our lab (23). Repeated quantitative 
radioimmunoassays found that, compared to control cells, cells treated with MBCD showed 
barely any cAMP production, just like is seen here in the CANDLES assay. However, this data 
also shows that when the MBCD was washed off of the cells and they were allowed to recover 
for an hour, cAMP production began to increase in the same pattern seen in the control cells, 
demonstrating that the MBCD treatment was not killing the cells to result in a lack of cAMP 
production, but rather was affecting cAMP production in a different way. Lastly, when the cells 
were treated with cholesterol after MBCD treatment and allowed to recover, cAMP production 
increased more rapidly, still in the same pattern as seen in the control cells (23). This 
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radioimmunoassay protocol has not been performed in our lab for about ten years because it 
exposes the assayer to radioactivity, which has been shown to correlate with higher incidence of 
cancer. The CANDLES assay is the first quantitative assay we have been able to perform in the 
lab since the radioimmunoassay, so the success of the method is significant for ongoing research, 
even if the data does not support our current hypotheses. Further, the data from the CANDLES 
assay is more compelling because it agrees with the last quantitative data we were able to collect 
in the lab. 
These results could be explained if caveolin and/or cholesterol were involved in hFSHR 
signaling in other ways. For example, the human beta-2-adrenergic receptor has been found to 
bind to cholesterol and subsequently take on an alternate structure (24). This alternate structure 
has been found to be the more functional structure of the receptor, making cholesterol an 
allosteric regulator for receptor function (25). The role of cholesterol and the role of lipid rafts in 
this signaling regulation could be further separated through a sphingolipid depletion 
experimental design. Fumonisin B​1 ​has a structure very similar to that of sphingolipids, allowing 
fumonisin B​1 ​treatment to interfere with sphingolipid synthesis in cells (26). Therefore, treatment 
with fumonisin B​1 ​would eliminate lipid rafts in the plasma membrane, but leave the cholesterol 
content of the cell unchanged. The CANDLES assay could be used to quantify cAMP production 
after sphingolipid depletion, which would allow for any effects of lipid raft disruption on 
signaling to be detected without the convolution of other effects of cholesterol depletion on 
signaling making the data less clear.  
Based on the data from the western blots, caveolin does seem to be involved in signaling 
somehow, but possibly not through lipid rafts, given the MBCD treatment data. Caveolin has 
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been found to exist stably as a soluble protein with its own functions in such an environment, but 
since the caveolin interaction motif of hFSHR is found in the fourth transmembrane domain, it 
would be unlikely that any of the functions of caveolin in a soluble state would be relevant here 
(27). However, the described functions of caveolin as an integral protein are all related to its 
presence in caveolae lipid rafts. This data could be alluding to a currently undescribed function 
of caveolin in the membrane separate from caveolae. The CANDLES assay should be 
re-attempted on the hFSHR caveolin interaction motif mutants to obtain quantitative data 
regarding the role of the motif in signaling for comparison to both the western blotting data from 
the mutants and the CANDLES data from the MBCD treatment. 
 
Acknowledgements 
I would like to thank Professor Brian Cohen, my research advisor, for his guidance and 
instruction throughout this project, without which it would not have been completed. I would 
also like to thank all members of Team Cohen for their support and assistance throughout the 
past year. Lastly, I would like to thank the Union College Biology Department, Faculty Research 
Funds, Student Research Grants, and the Davenport Summer Research Fellowship for the 




1. Infertility | Reproductive Health | CDC [Internet].; 2019 [updated -01-16T05:43:25Z/; cited 
Apr 2, 2019]. Available from: https://www.cdc.gov/reproductivehealth/infertility/index.htm. 
2. Infertility - Diagnosis and Treatment [Internet].; 2018 [updated March 8,; cited April 4, 2019]. 
Available from: 
https://www.mayoclinic.org/diseases-conditions/infertility/diagnosis-treatment/drc-20354322. 
3. Treating Infertility [Internet].; 2017 [updated October; ]. Available from: 
https://www.acog.org/Patients/FAQs/Treating-Infertility?IsMobileSet=false#treatment. 
4. Katz, Patricia, Ph.D.|Showstack, Jonathan, Ph.D., M.P.H.|Smith, James F., M.D., 
M.S.|Nachtigall, Robert D., M.D.|Millstein, Susan G., Ph.D.|Wing, Holly, M.A.|Eisenberg, 
Michael L., M.D.|Pasch, Lauri A., Ph.D.|Croughan, Mary S., Ph.D.|Adler, Nancy, Ph.D. Costs of 
infertility treatment: results from an 18-month prospective cohort study. Fertility and Sterility. 
2011;95(3):915-21. 
5. Fertility and Mental Health.  
6. Holt RI, Hanley NA. Essential Endocrinology and Diabetes. 6th ed. West Sussex, UK: 
Wiley-Blackwell; 2012. 
7. Hormonal Control of Human Reproduction [Internet]. [cited April 2, 2019]. 
8. Hunzicker-Dunn M, Maizels ET. FSH signaling pathways in immature granulosa cells that 
regulate target gene expression: branching out from protein kinase A. Cell  Signal. 2006 
Sep;18(9):1351-9. 
9. McKenzie KA, Cohen B. Investigation of Human Follicle Stimulating Hormone Residency in 
Membrane Microdomains [dissertation]. Union College; 2009. 
10. Brown DA, London E. FUNCTIONS OF LIPID RAFTS IN BIOLOGICAL MEMBRANES. 
Annual Review of Cell and Developmental Biology. 1998 Nov;14(1):111-36. 
11. Dart C. Lipid microdomains and the regulation of ion channel function. J Physiol. 2010 Sep 
1;588(Pt 17):3169-78. 
12. Quest AF, Leyton L, Parraga M. Caveolins, caveolae, and lipid rafts in cellular transport, 
signaling, and disease. Biochem Cell Biol. 2004 Feb;82(1):129-44. 
13. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, et al. Evidence for a 
regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem. 1995 June 
30,;270(26):15693-701. 
14. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal 
transduction molecules. Annual review of pharmacology and toxicology. 2008;48(1):359-91. 
15. Byrne DP, Dart C, Rigden DJ. Evaluating caveolin interactions: do proteins interact with the 
caveolin scaffolding domain through a widespread aromatic residue-rich motif? PLoS One. 
2012;7(9):e44879. 
16. Mahammad S, Parmryd I. Cholesterol depletion using methyl-β-cyclodextrin. Methods Mol 
Biol. 2015;1232:91-102. 
17. Allen JA, Yu JZ, Dave RH, Bhatnagar A, Roth BL, Rasenick MM. Caveolin-1 and lipid 
microdomains regulate Gs trafficking and attenuate Gs/adenylyl cyclase signaling. Mol 
Pharmacol. 2009 August 20,. 
18. Wells M, Cohen B. Follicle Stimulating Hormone Receptor Signaling is Regulated by Lipid 
Raft Residency. Experimental Biology; April 2018; . 
19. Thomas P, Smart TG. HEK293 cell line: a vehicle for the expression of recombinant 
proteins. J Pharmacol Toxicol Methods. 2005 May-Jun;51(3):187-200. 
Altman 28 
20. Instruction Manual. Q5® Site-Directed Mutagenesis Kit (Without Competent Cells).  
21. TransIT®-293 Transfection Reagent Protocol for MIR 2700, 2704, 2705, 2706<br>. 
Protocol. 2007. 
22. Trehan A, Rotgers E, Coffey ET, Huhtaniemi I, Rivero-Müller A. CANDLES, an assay for 
monitoring GPCR induced cAMP generation in cell cultures. Cell Commun  Signal. 2014 Nov 
04,;12:70. 
23. Cohen B. Set adrift on membrane bliss: Human follicle stimulating hormone receptor activity 
is lipid raft dependent. ; 2008. 
24. Hanson MA, Cherezov V, Roth CB, Griffith MT, Jaakola V, Chien EYT, et al. A specific 
cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor 
in an alternate crystal form. Structure. 2008 Jun 1,;16(6):897-905. 
25. Manna M, Niemelä M, Tynkkynen J, Javanainen M, Kulig W, Müller DJ, et al. Mechanism 
of allosteric regulation of β2-adrenergic receptor by cholesterol. eLife. 2016 Nov 1,;5. 
26. Stockmann-Juvala H, Savolainen K. A review of the toxic effects and mechanisms of action 
of fumonisin B1. Hum Exp Toxicol. 2008 November 1,;27(11):799-809. 
27. Smart EJ, Ying YS, Conrad PA, Anderson RG. Caveolin moves from caveolae to the Golgi 
apparatus in response to cholesterol oxidation. . 1994 Dec 1;127(5). 
